



NOTICE OF MEETING

NOXOPHARM 2016 AGM Sydney Briefing

November 25, 2016 at 4pm

ASX: NOX

Noxopharm Limited

ABN 50 608 966 123

Registered Office:

Suite 1 Level 6
50 Queen St
Melbourne VIC 3000
Australia

Board of Directors

Mr Peter Marks

Chairman
Non-Executive
Director

Dr Graham Kelly

Chief Executive Officer
Managing Director

Dr Ian Dixon

Non-Executive
Director

Following the Company's AGM in Melbourne on November 23, 2016, Noxopharm Limited (ASX: NOX) will be holding an AGM Sydney Briefing on November 25th at 4pm at the Grace Hotel, 77 York Street, Sydney.

Attendees will have the opportunity to meet with the Noxopharm Board of Directors.

CEO, Dr Graham Kelly, also will review the Company's clinical trial programme and general drug development strategy.

Please RSVP for this event to: Prue Kelly info@noxopharm.com or call Noxopharm + 61 2 91442223

About Noxopharm

Noxopharm is an Australian drug development company with offices in Melbourne and Sydney. The Company has a primary focus on the development of drugs to address the problem of drug-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development in an R&D program.